IDIOPATHIC PULMONARY FIBROSIS

This study tests an experimental drug called BMS-986278 in about 1,255 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if the drug can slow lung function decline and is safe. Participants must be 40 or o…

This study tests a new tablet called HEC585 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 270 adults aged 40-80 will take either HEC585, a placebo, or an existing drug (pirfenidone) for 24 weeks. The main …

This study looks at the long-term safety of an inhaled medication called treprostinil for people with lung scarring conditions like idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 1,850 adults who have already taken part in a related study will …

This early-stage study tests whether atezolizumab, a drug used for certain cancers, is safe and shows promise for treating idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Resea…

This study tests a new drug called LYT-100 in 240 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing harder. The goal is to see if LYT-100 can slow the decline in lung function better than an existing drug (pirfenidone…

This study tests an experimental drug called ENV-101 in 213 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if ENV-101 can improve lung function and slow disease progression compared to a placebo. Partic…

This phase 2 trial tests whether the investigational drug CAL101 can slow the loss of lung function in adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. About 150 participants will receive either CAL101 or a placebo by IV infusion once a month for 6…

This study tests a drug called axatilimab in 145 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The goal is to see if axatilimab can slow the decline in lung function over 26 weeks compared to a placebo. Participants…

This study looks at whether a special MRI scan using inhaled xenon gas can show changes in lung function for people with idiopathic pulmonary fibrosis (IPF) who are starting approved treatments. About 34 adults with IPF will have the scan before starting therapy and again at 3, 6…

This study at Duke University is testing whether a special type of MRI (using xenon gas) can show how well antifibrotic medicines are working in people with progressive lung scarring. About 60 adults with interstitial lung disease will get this MRI before starting treatment and a…

This study looks at whether a molecule called miR200 in the blood can help identify early signs of idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Researchers will compare miR200 levels in 450 people: those with IPF, those with other lung diseases, and healthy volun…